 |
7 Diseases |  |
10 Trials |
|
10 Trials |  |
866 News |  |
| «123456789» |
- | Fiasp (fast-acting insulin aspart) / Novo Nordisk
New trial: Closed-Loop With Faster Aspart in Young Adults With Type 1 Diabetes (clinicaltrials.gov) - Jul 11, 2017
P=N/A, N=20, Not yet recruiting, Sponsor: University of Ljubljana, Faculty of Medicine
- || Fiasp (fast-acting insulin aspart) / Novo Nordisk
Trial initiation date, Trial primary completion date: A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Faster-acting Insulin Aspart in Subjects With Type 2 Diabetes Mellitus (clinicaltrials.gov) - Jul 2, 2017
P1, N=60, Recruiting, Sponsor: Novo Nordisk A/S
Initiation date: Oct 2016 --> Dec 1956 | Trial primary completion date: Apr 2017 --> Oct 2017
- | Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
New P1 trial: A Trial to Evaluate the Pharmacokinetic and Pharmacodynamic Properties of BioChaperone (clinicaltrials.gov) - Jun 7, 2017
P1, N=42, Recruiting, Sponsor: Adocia
- Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
Trial primary completion date: SNIFF-Quick: Study of Nasal Insulin to Fight Forgetfulness - Short-Acting Insulin Aspart (clinicaltrials.gov) - Apr 19, 2017
P1, N=30, Recruiting, Sponsor: Wake Forest University Health Sciences
Initiation date: Oct 2016 --> Dec 1956 | Trial primary completion date: Apr 2017 --> Oct 2017 Trial primary completion date: Dec 2016 --> Jul 2018
- ||||| Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
Enrollment closed: Efficacy and Safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart Compared to NovoRapid (clinicaltrials.gov) - Jan 30, 2017
P3, N=450, Active, not recruiting, Sponsor: Novo Nordisk A/S
Trial primary completion date: Dec 2016 --> Jul 2018 Recruiting --> Active, not recruiting
- ||||| Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
Enrollment closed, Combination therapy: onset (clinicaltrials.gov) - Nov 28, 2016
P3, N=1130, Active, not recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||| Fiasp (fast-acting insulin aspart) / Novo Nordisk
Enrollment open: A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Faster-acting Insulin Aspart in Subjects With Type 2 Diabetes Mellitus (clinicaltrials.gov) - Nov 12, 2016
P1, N=60, Recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||| Fiasp (fast-acting insulin aspart) / Novo Nordisk
New P1 trial: A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Faster-acting Insulin Aspart in Subjects With Type 2 Diabetes Mellitus (clinicaltrials.gov) - Oct 13, 2016
P1, N=60, Not yet recruiting, Sponsor: Novo Nordisk A/S
- |||||| Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
Enrollment open: Efficacy and Safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart Compared to NovoRapid (clinicaltrials.gov) - Aug 5, 2016
P3, N=450, Recruiting, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||| Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
Trial primary completion date, Combination therapy: onset (clinicaltrials.gov) - Jul 27, 2016
P3, N=833, Recruiting, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2017 --> Mar 2018
- |||||||||| Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
New P3 trial: Efficacy and Safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart Compared to NovoRapid (clinicaltrials.gov) - Jul 7, 2016
P3, N=450, Not yet recruiting, Sponsor: Novo Nordisk A/S
- |||||| Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
Enrollment open, Combination therapy: onset (clinicaltrials.gov) - May 12, 2016
P3, N=1130, Recruiting, Sponsor: Novo Nordisk A/S
Trial primary completion date: Dec 2017 --> Mar 2018 Not yet recruiting --> Recruiting
- |||||| Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
Enrollment open, Combination therapy: onset (clinicaltrials.gov) - May 5, 2016
P3, N=833, Recruiting, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Fiasp (fast-acting insulin aspart) / Novo Nordisk
Trial completion: Investigating the Postprandial Glucose Metabolism After Treatment With Faster-acting Insulin Aspart in Subjects With Type 1 Diabetes (clinicaltrials.gov) - May 2, 2016
P1, N=42, Completed, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Fiasp (fast-acting insulin aspart) / Novo Nordisk
Enrollment closed: Investigating the Postprandial Glucose Metabolism After Treatment With Faster-acting Insulin Aspart in Subjects With Type 1 Diabetes (clinicaltrials.gov) - Apr 6, 2016
P1, N=38, Active, not recruiting, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||||||||| Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
New P3 trial, Combination therapy: onset (clinicaltrials.gov) - Feb 2, 2016
P3, N=833, Not yet recruiting, Sponsor: Novo Nordisk A/S
- Fiasp (fast-acting insulin aspart) / Novo Nordisk
Enrollment open: Investigating the Postprandial Glucose Metabolism After Treatment With Faster-acting Insulin Aspart in Subjects With Type 1 Diabetes (clinicaltrials.gov) - Nov 1, 2015
P1, N=38, Recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | Fiasp (fast-acting insulin aspart) / Novo Nordisk
New P1 trial: Investigating the Postprandial Glucose Metabolism After Treatment With Faster-acting Insulin Aspart in Subjects With Type 1 Diabetes (clinicaltrials.gov) - Oct 5, 2015
P1, N=38, Not yet recruiting, Sponsor: Novo Nordisk A/S
- || Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
New P3 trial, Combination therapy: onset (clinicaltrials.gov) - Jul 16, 2015
P3, N=1130, Not yet recruiting, Sponsor: Novo Nordisk A/S
- | Levemir (insulin detemir rDNA origin) / Novo Nordisk, Fiasp (fast-acting insulin aspart) / Novo Nordisk
Trial completion, Combination therapy: Efficacy and Safety of FIAsp Compared to Insulin Aspart Both in Combination With Insulin Detemir in Adults With Type 1 Diabetes (clinicaltrials.gov) - Jun 23, 2015
P3, N=1290, Completed, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
New P1 trial: SNIFF-Quick: Study of Nasal Insulin to Fight Forgetfulness - Short-Acting Insulin Aspart (clinicaltrials.gov) - Jun 3, 2015
P1, N=30, Recruiting, Sponsor: Wake Forest School of Medicine
- | Fiasp (fast-acting insulin aspart) / Novo Nordisk
Trial completion, Enrollment change, Combination therapy: onset 2: Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes (clinicaltrials.gov) - Jan 26, 2015
P3, N=881, Completed, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=676 --> 881
- | Fiasp (fast-acting insulin aspart) / Novo Nordisk
Trial completion, Combination therapy: Efficacy and Safety of FIAsp in a Basal-bolus Regimen Versus Basal Insulin Therapy, Both in Combination With Metformin in Adult Subjects With Type 2 Diabetes (clinicaltrials.gov) - Nov 24, 2014
P3, N=323, Completed, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed | N=676 --> 881 Active, not recruiting --> Completed
- Fiasp (fast-acting insulin aspart) / Novo Nordisk
Trial completion: A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp in Geriatric and Younger Adult Subjects With Type 1 Diabetes (clinicaltrials.gov) - Aug 19, 2014
P1, N=67, Completed, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Fiasp (fast-acting insulin aspart) / Novo Nordisk
Enrollment closed: A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp in Geriatric and Younger Adult Subjects With Type 1 Diabetes (clinicaltrials.gov) - Aug 5, 2014
P1, N=67, Active, not recruiting, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Fiasp (fast-acting insulin aspart) / Novo Nordisk
Trial completion: A Randomised Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Faster-acting Insulin Aspart in Subjects With Type 1 Diabetes (clinicaltrials.gov) - Aug 5, 2014
P1, N=33, Completed, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Fiasp (fast-acting insulin aspart) / Novo Nordisk
Trial completion: A Trial Investigating the Pharmacokinetic Properties of FIAsp in Children, Adolescents and Adults With Type 1 Diabetes (clinicaltrials.gov) - Jul 30, 2014
P1, N=41, Completed, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Fiasp (fast-acting insulin aspart) / Novo Nordisk
Enrollment closed: A Randomised Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Faster-acting Insulin Aspart in Subjects With Type 1 Diabetes (clinicaltrials.gov) - Jul 17, 2014
P1, N=32, Active, not recruiting, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Fiasp (fast-acting insulin aspart) / Novo Nordisk
Enrollment closed: A Trial Investigating the Pharmacokinetic Properties of FIAsp in Children, Adolescents and Adults With Type 1 Diabetes (clinicaltrials.gov) - Jul 17, 2014
P1, N=39, Active, not recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Fiasp (fast-acting insulin aspart) / Novo Nordisk
Trial primary completion date: A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp in Geriatric and Younger Adult Subjects With Type 1 Diabetes (clinicaltrials.gov) - Jul 1, 2014
P1, N=67, Recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Trial primary completion date: Mar 2014 --> Aug 2014
- Fiasp (fast-acting insulin aspart) / Novo Nordisk
Enrollment change: A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp in Geriatric and Younger Adult Subjects With Type 1 Diabetes (clinicaltrials.gov) - Jul 1, 2014
P1, N=67, Recruiting, Sponsor: Novo Nordisk A/S
Trial primary completion date: Mar 2014 --> Aug 2014 N=44 --> 67
- Fiasp (fast-acting insulin aspart) / Novo Nordisk
Enrollment open, Enrollment change, Trial primary completion date: A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp in Geriatric and Younger Adult Subjects With Type 1 Diabetes (clinicaltrials.gov) - Jul 1, 2014
P1, N=67, Recruiting, Sponsor: Novo Nordisk A/S
N=44 --> 67 Completed --> Recruiting | N=44 --> 67 | Trial primary completion date: Mar 2014 --> Aug 2014
- Fiasp (fast-acting insulin aspart) / Novo Nordisk
Trial completion: A Trial Investigating the Pharmacodynamic Response of Faster Acting Insulin Aspart in Subjects With Type 1 Diabetes (clinicaltrials.gov) - Jul 1, 2014
P1, N=46, Completed, Sponsor: Novo Nordisk A/S
Completed --> Recruiting | N=44 --> 67 | Trial primary completion date: Mar 2014 --> Aug 2014 Active, not recruiting --> Completed
- Fiasp (fast-acting insulin aspart) / Novo Nordisk
Enrollment closed: A Trial Investigating the Pharmacodynamic Response of Faster Acting Insulin Aspart in Subjects With Type 1 Diabetes (clinicaltrials.gov) - Jun 18, 2014
P1, N=46, Active, not recruiting, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Fiasp (fast-acting insulin aspart) / Novo Nordisk
Trial completion: A Trial Comparing the Pharmacokinetic Properties of Faster-acting Insulin Aspart (FIAsp) After Different Injection Regions and Routes of Administration in Healthy Subjects (clinicaltrials.gov) - Jun 13, 2014
P1, N=19, Completed, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Recruiting --> Completed
- Fiasp (fast-acting insulin aspart) / Novo Nordisk
Trial completion: onset (clinicaltrials.gov) - May 27, 2014
P3, N=37, Completed, Sponsor: Novo Nordisk A/S
Recruiting --> Completed Active, not recruiting --> Completed
- Fiasp (fast-acting insulin aspart) / Novo Nordisk
Enrollment open: A Randomised Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Faster-acting Insulin Aspart in Subjects With Type 1 Diabetes (clinicaltrials.gov) - May 5, 2014
P1, N=32, Recruiting, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Fiasp (fast-acting insulin aspart) / Novo Nordisk
New P1 trial: A Randomised Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Faster-acting Insulin Aspart in Subjects With Type 1 Diabetes (clinicaltrials.gov) - May 4, 2014
P1, N=32, Not yet recruiting, Sponsor: Novo Nordisk A/S
- | Fiasp (fast-acting insulin aspart) / Novo Nordisk
Enrollment closed, Combination therapy: onset 2: Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes (clinicaltrials.gov) - Apr 27, 2014
P3, N=676, Active, not recruiting, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | Fiasp (fast-acting insulin aspart) / Novo Nordisk
Enrollment change, Combination therapy: Efficacy and Safety of FIAsp in a Basal-bolus Regimen Versus Basal Insulin Therapy, Both in Combination With Metformin in Adult Subjects With Type 2 Diabetes (clinicaltrials.gov) - Apr 7, 2014
P3, N=286, Active, not recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting N=218 --> 286
- | Fiasp (fast-acting insulin aspart) / Novo Nordisk
Enrollment closed, Combination therapy: Efficacy and Safety of FIAsp in a Basal-bolus Regimen Versus Basal Insulin Therapy, Both in Combination With Metformin in Adult Subjects With Type 2 Diabetes (clinicaltrials.gov) - Apr 7, 2014
P3, N=286, Active, not recruiting, Sponsor: Novo Nordisk A/S
N=218 --> 286 Recruiting --> Active, not recruiting
- Fiasp (fast-acting insulin aspart) / Novo Nordisk
Trial completion: A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp in Geriatric and Younger Adult Subjects With Type 1 Diabetes (clinicaltrials.gov) - Mar 23, 2014
P1, N=44, Completed, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Fiasp (fast-acting insulin aspart) / Novo Nordisk
Enrollment open: A Trial Comparing the Pharmacokinetic Properties of Faster-acting Insulin Aspart (FIAsp) After Different Injection Regions and Routes of Administration in Healthy Subjects (clinicaltrials.gov) - Mar 18, 2014
P1, N=20, Recruiting, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Fiasp (fast-acting insulin aspart) / Novo Nordisk
New P1 trial: A Trial Comparing the Pharmacokinetic Properties of Faster-acting Insulin Aspart (FIAsp) After Different Injection Regions and Routes of Administration in Healthy Subjects (clinicaltrials.gov) - Mar 13, 2014
P1, N=20, Recruiting, Sponsor: Novo Nordisk A/S
- | Levemir (insulin detemir rDNA origin) / Novo Nordisk, Fiasp (fast-acting insulin aspart) / Novo Nordisk
Enrollment closed, Combination therapy: Efficacy and Safety of FIAsp Compared to Insulin Aspart Both in Combination With Insulin Detemir in Adults With Type 1 Diabetes (clinicaltrials.gov) - Mar 9, 2014
P3, N=1095, Active, not recruiting, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | Fiasp (fast-acting insulin aspart) / Novo Nordisk
Trial completion: A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp When Administered as a Bolus in a Continuous Subcutaneous Infusion Regimen in Subjects With Type 1 Diabetes (clinicaltrials.gov) - Mar 9, 2014
P1, N=48, Completed, Sponsor: Novo Nordisk
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Fiasp (fast-acting insulin aspart) / Novo Nordisk
Enrollment closed: onset (clinicaltrials.gov) - Feb 25, 2014
P3, N=36, Active, not recruiting, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | Fiasp (fast-acting insulin aspart) / Novo Nordisk
Trial completion: A Trial Investigating the Pharmacokinetic Properties of FIAsp in Japanese Subjects With Type 1 Diabetes (clinicaltrials.gov) - Jan 27, 2014
P1, N=43, Completed, Sponsor: Novo Nordisk
Recruiting --> Active, not recruiting Recruiting --> Completed
- Fiasp (fast-acting insulin aspart) / Novo Nordisk
Enrollment open: A Trial Investigating the Pharmacodynamic Response of Faster Acting Insulin Aspart in Subjects With Type 1 Diabetes (clinicaltrials.gov) - Jan 20, 2014
P1, N=46, Recruiting, Sponsor: Novo Nordisk
Recruiting --> Completed Not yet recruiting --> Recruiting
- Fiasp (fast-acting insulin aspart) / Novo Nordisk
Enrollment open: A Trial Investigating the Pharmacokinetic Properties of FIAsp in Children, Adolescents and Adults With Type 1 Diabetes (clinicaltrials.gov) - Jan 13, 2014
P1, N=39, Recruiting, Sponsor: Novo Nordisk
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting